Dosing and uses of Attenuvax (measles (rubeola) vaccine)
Adult dosage forms and strengths
vaccine
- lyophilized supplied with diluent
Measles Vaccination
0.5 mL SC
Additional Information
Up-to-date vaccination schedules available at www.cdc.gov/nip/publications
Other Indications & Uses
(MMR preferred)
Pediatric dosage forms and strengths
vaccine
- lyophilized supplied with diluent
Measles Vaccination
<12 months old: 0.5 mL SC; give additional dose between 12-15 months old
>12 months old: 0.5 mL SC
Revaccination with MMR-II recommended before elementary school entry
Attenuvax (measles (rubeola) vaccine) adverse (side) effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
>10%
Fever (5-15%)
1-10%
Rash (5%)
Frequency not defined
Pain at site
Syncope
Headache
Dizziness
Malaise
Irritability
Encephalitis
Guillain-Barre synd
Subacute sclerosing panencephalitis (rare)
Seizure
Thrombocytopenia
Stevens-Johnson syndrome
Warnings
Contraindications
Pregnancy
Hypersensitivity to eggs, neomycin, gelatin
Immunosuppression secondary to CA, AIDS, therapy, etc
Concurrent Immune Globulins or immunosuppressive drugs
Blood dyscrasias, hematologic cancers
Congenital immunodeficiency
Febrile respiratory illness or other active febrile infection
- minor infections can be exempted
Cautions
Trivalent MMR is preferred agent
Those born prior to 1957 are generally considered immune
Avoid pregnancy for 3 mth after vaccination
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if excreted in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Attenuvax (measles (rubeola) vaccine)
Duration: Unknown
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
Pharmacogenomics
HLA-B7, HLA-B51, HLA-DRB1*13, and HLADQA1*01 is associated with a measles vaccine response
Homozygosity at HLA-B, HLA-DR, and HLA-DQA1 has been associated with a measles vaccine nonresponse
Mechanism of action
Live, attenuated measles virus stimulates active immunity
